The growth advantage and resistance to therapy in NSCLC patients with a worse prognosis are associated with the activation of the NRF2 pathway, contributing to a higher expression of multidrug-resistant protein-3 [58]. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.